Protection of cisplatin-induced neuropathy: recent developments.
Hamers
F
F
Department of Medical Pharmacology, Rudolf Magnus Institute, Utrecht, The Netherlands.
Neijt
J
J
Gispen
W
W
D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004999:Amifostine / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005978:Glutathione / Q000627:therapeutic use*; D006801:Humans; D009422:Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010446:Peptide Fragments / Q000627:therapeutic use*
D000927:Anticonvulsants; D010446:Peptide Fragments; C013765:Org 2766; D000324:Adrenocorticotropic Hormone; D005978:Glutathione; D004999:Amifostine; D002945:Cisplatin